NCT/Study#
NCT07140016 /
2215-CL-5201
A Phase 1b Study of Gilteritinib in Participants with Locally Advanced or Metastatic NSCLC with ALK Rearrangement After Prior Treatment with an ALK Inhibitor
DISEASE GROUP:
NSCLC
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
